How does startup stock options work?

Startup stock options are a contract that gives you the right (not the obligation) to buy company shares later at a fixed price. If the company’s value rises, you can buy at the old price and potentially profit when you sell. If the company doesn’t grow or never exits, options can end up worth $0.

In medtech, options can be especially confusing because timelines are long (clinical validation, FDA pathway like 510(k)/De Novo/PMA, reimbursement, hospital procurement). That means your options may vest for years before there’s a clear liquidity event (acquisition or IPO). Understanding the mechanics early prevents expensive surprises.

1) The core pieces: grant, strike price, vesting, and expiration

Every option grant has a few standard terms:

• Number of options: how many shares you can buy later.
• Strike price (exercise price): the price you’ll pay per share when you exercise. Typically set to the company’s fair market value (FMV) at the time of grant (often based on a 409A valuation in the US).
• Vesting schedule: when you earn the right to exercise. The most common is 4 years with a 1-year cliff (you vest 0% until month 12, then 25%, then monthly/quarterly thereafter).
• Expiration: options usually expire 10 years from grant (varies by plan).

Example: You receive 20,000 options with a $1.00 strike price. After 1 year (the cliff), 5,000 vest. If you leave at 18 months, you might have ~7,500 vested (depending on monthly vesting), and the rest are forfeited.

What “exercise” means

Exercising is paying the strike price to convert options into actual shares. If you have 5,000 vested options at a $1 strike, exercising costs $5,000 (plus potential taxes and paperwork). Until you exercise, you do not own shares.

The post-termination exercise window (PTEW) is a big deal

Many plans require you to exercise within a short window after leaving the company (commonly 90 days for ISOs; terms vary). In medtech, where exits can take longer, a short PTEW can force a tough choice: pay cash (and possibly taxes) to keep upside, or walk away from vested options.

2) ISO vs NSO: the two main types (and why founders should care)

In the US, employee options are usually either ISOs (Incentive Stock Options) or NSOs (Nonqualified Stock Options). The difference is mostly tax treatment and eligibility rules.

• ISOs: typically for employees only. Potentially favorable tax treatment if you meet holding requirements, but can trigger AMT (Alternative Minimum Tax) depending on your situation.
• NSOs: can be granted to employees, contractors, advisors. Often taxed as ordinary income on the “spread” (difference between FMV and strike) at exercise (details vary).

Because taxes depend heavily on jurisdiction and personal circumstances, treat any option decision as a cash + tax planning problem, not just an “equity upside” problem. If you’re considering early exercise, leaving the company, or exercising close to an acquisition, it’s worth getting a tax professional who has handled startup equity before.

3) How options translate into ownership: cap table, option pool, and dilution

Options are slices of a bigger pie called the cap table (capitalization table): who owns what (founders, employees, investors, option pool). Your ownership percentage is:

your shares (after exercise) / total shares outstanding (often fully diluted)

Fully diluted usually means counting all shares that could exist if everyone exercised options and all convertible instruments converted. Investors and acquirers often think in fully diluted terms.

Option pool

Startups create an option pool (often 10–20% early on, but it varies) reserved for employee/advisor grants. When a company raises a priced round, investors may require the pool to be “topped up,” which can dilute existing holders (including founders and earlier employees).

Dilution in plain language

Dilution means your percentage ownership can go down as the company issues more shares (new investment rounds, expanding option pool). Importantly, dilution is not automatically bad if the company’s value increases more than your percentage decreases.

Medtech nuance: medtech companies often raise multiple rounds to fund verification/validation, clinical studies (sometimes under IRB approval), regulatory work (510(k), De Novo, PMA), and commercialization (reimbursement strategy, hospital procurement cycles). More rounds can mean more dilution before an exit.

4) What makes options valuable (or worthless): liquidity, preferences, and timelines

Options only become “real money” when you can sell shares, usually at:

• Acquisition (common in medtech)
• IPO (less common)
• Secondary sale (sometimes, but not guaranteed)

Exit value vs your payout: liquidation preferences

Investors often have liquidation preferences, meaning they may get paid first (up to a certain amount) before common shareholders (founders/employees) receive proceeds. This is standard venture financing. The details (1x non-participating, participating, etc.) vary by deal.

Why this matters: a headline acquisition price does not automatically mean common shareholders get that price pro-rata. Preferences and other terms can change the distribution.

Medtech timelines change the “expected value” of options

In software, a company might reach meaningful revenue quickly. In medtech, value inflection points often depend on milestones like:

• Regulatory clearance/approval (510(k), De Novo, PMA)
• Clinical evidence generation (often with IRB oversight when applicable)
• Reimbursement progress (coverage decisions, coding like CPT where relevant, payment levels)
• Hospital procurement adoption (vendor onboarding, GPOs, committees, budget cycles)

This can mean your options vest long before the company’s valuation meaningfully increases. It doesn’t make options bad; it means you should evaluate them with a longer horizon and more uncertainty.

5) How to evaluate an offer: a practical checklist for medtech founders and early hires

When someone says “we’re offering you options,” the useful question is: options for how much of the company, under what terms, and under what realistic exit path?

1. Ask for the fully diluted share count and your grant size. Convert to a percentage: options / fully diluted shares.
2. Confirm the vesting schedule (4 years/1-year cliff is common) and whether any acceleration exists (single-trigger or double-trigger on acquisition; varies).
3. Check the PTEW (how long you have to exercise after leaving). This can be more important than the number of options.
4. Understand the strike price and whether the company has a recent 409A valuation (US). A very high strike can reduce practical upside.
5. Clarify ISO vs NSO and whether you’re an employee or contractor. This affects taxes and deadlines.
6. Ask about the financing plan: expected future rounds before key milestones (regulatory, clinical, reimbursement). More rounds usually mean more dilution.
7. Sanity-check the exit narrative: In medtech, acquisitions often happen around specific milestones (varies by category). Ask what milestone the company believes drives strategic buyer interest.

Rule of thumb: Don’t evaluate options using only the company’s current “paper valuation.” Evaluate (1) probability of a liquidity event, (2) time to that event, (3) dilution and preferences, and (4) your ability to exercise without taking on unacceptable cash/tax risk.

What to do next

1. Convert your grant to a percentage using fully diluted shares, and write it down next to vesting and PTEW terms.
2. Request the option plan + grant agreement and highlight: expiration, exercise rules, change-of-control treatment, and termination clauses.
3. Map medtech milestones to your vesting timeline (e.g., expected 510(k)/De Novo/PMA timing, clinical study timeline, reimbursement steps, procurement cycle) to see if you’ll be vested before value inflection.
4. Build a simple dilution scenario (current fully diluted shares, expected new rounds, option pool top-ups) to estimate your future percentage.
5. Get a tax-aware exercise plan before you leave a company or before an acquisition rumor cycle starts (details vary by jurisdiction and personal situation).